Department of Cardiology, SCTIMST, Trivandrum, India.
Department of Cardiology, SCTIMST, Trivandrum, India.
Indian Heart J. 2022 Jan-Feb;74(1):34-39. doi: 10.1016/j.ihj.2021.12.002. Epub 2021 Dec 14.
Short term outcomes of patients with pulmonary hypertension are not available from low and middle-income countries including India.
We conducted a prospective study of 2003 patients with pulmonary hypertension, from 50 centres (PROKERALA) in Kerala, who were followed up for one year. Pulmonary hypertension (PH) was mainly diagnosed on the basis of Doppler echocardiography. The primary outcome was a composite end-point of all-cause death and hospital admission for heart failure. All cause hospitalisation events constituted the secondary outcome.
Mean age of study population was 56 ± 16 years. Group 1 and Group 2 PH categories constituted 21.2% and 59% of the study population, respectively. Nearly two-thirds (65%) of the study participants had functional class II symptoms. 31% of Group 1 PH patients were on specific vasodilator drugs.In total, 83 patients (4.1%) died during the one-year follow-up period. Further, 1235 re-hospitalisation events (61.7%) were reported. In the multivariate model, baseline NYHA class III/IV (OR 1.87, 95% C.I. 1.35-2.56), use of calcium channel blockers (OR 0.18, 95% C.I. 0.04-0.77), vasodilator therapy (OR 0.5, 95% C.I. 0.28-0.87) and antiplatelet agents (OR 1.80, 95% C.I. 1.29-2.51) were associated with primary composite outcome at one-year (p < 0.05).
In the PROKERALA registry, annual mortality rate was 4%. More than half of the patients reported re-hospitalisation events on follow up. Uptake of guideline directed therapies were suboptimal in the study population. Quality improvement programmes to improve guideline directed therapy may improve clinical outcomes of PH patients in India.
包括印度在内的中低收入国家缺乏肺动脉高压患者的短期预后数据。
我们对来自喀拉拉邦 50 个中心(PROKERALA)的 2003 例肺动脉高压患者进行了前瞻性研究,随访时间为 1 年。肺动脉高压(PH)主要基于多普勒超声心动图进行诊断。主要终点是全因死亡和心力衰竭住院的复合终点。全因住院事件构成次要终点。
研究人群的平均年龄为 56±16 岁。第 1 组和第 2 组 PH 类别分别占研究人群的 21.2%和 59%。近三分之二(65%)的研究参与者有 II 级功能症状。第 1 组 PH 患者中有 31%接受了特定的血管扩张药物治疗。在整个研究期间,有 83 名患者(4.1%)在 1 年的随访期间死亡。此外,有 1235 例再住院事件(61.7%)报告。在多变量模型中,基线纽约心脏协会(NYHA)III/IV 级(OR 1.87,95%CI 1.35-2.56)、钙通道阻滞剂的使用(OR 0.18,95%CI 0.04-0.77)、血管扩张治疗(OR 0.5,95%CI 0.28-0.87)和抗血小板药物(OR 1.80,95%CI 1.29-2.51)与 1 年时的主要复合结局相关(p<0.05)。
在 PROKERALA 登记处,年死亡率为 4%。超过一半的患者在随访期间报告再住院事件。研究人群中指南指导治疗的使用率不理想。改善指南指导治疗的质量改进计划可能会改善印度 PH 患者的临床结局。